Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome
2014-001834-27Phase 3Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cannabidiol in Dravet syndrome, Lennox-Gastaut syndrome (LGS) and myoclonic epilepsy of infancy (MEI), sponsored by GW Pharmaceuticals. Primary endpoints: Adverse event profile and Changes in safety parameters vs core study baseline. Started Sep 2014; status: completed.
02
Drugs
cannabidiol
03
Conditions
Dravet syndromeLennox-Gastaut syndrome (LGS)myoclonic epilepsy of infancy (MEI)
Beyond the preview
Go deeper on 2014-001834-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001834-27.